Multiple Myeloma Clinical Trials

Find clinical trials for multiple myeloma. Search for multiple myeloma clinical trials in different cities and states across the United States.

Filter

Filter results

Results: 299

CX-4945Dose-escalation Study of Oral CX-4945

Recruiting

PHASE1

Sponsor:

Cylene Pharmaceuticals

Location:

Scottsdale AZ, Fort Collins CO, Loveland CO, Houston TX

Code:

NCT00891280

Conditions

Advanced Solid Tumors

Breast Cancer

Inflammatory Breast Cancer

Castleman's Disease

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CX-4945 oral formulation

VSV-hIFNβ-NIS, Cyclophosphamide, Ipilimumab, Nivolumab, CemiplimabA Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting

PHASE1

Sponsor:

Mayo Clinic

Location:

Scottsdale AZ, Rochester MN

Code:

NCT03017820

Conditions

B-Cell Non-Hodgkin Lymphoma

Histiocytic and Dendritic Cell Neoplasm

Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Bone Marrow Biopsy

Computed Tomography

Cyclophosphamide

Daratumumab vs. DaratumumabFixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Recruiting

PHASE3

Sponsor:

Canadian Cancer Trials Group

Location:

Kelowna, Vancouver, Winnipeg, Monctonshow 16 more

Code:

NCT06182774

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daratumumab

Lenalidomide

Dexamethasone

Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Tucson AZ, Little Rock AR, Norwalk CT, Washington DCshow 29 more

Code:

NCT05455320

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talquetamab

Daratumumab

Pomalidomide

Dexamethasone

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Anchorage AK, Fairbanks AK, Kingman AZ, Phoenix AZshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

Geriatric AssessmentGeriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Recruiting

PHASE2

Sponsor:

City of Hope Medical Center

Location:

Duarte CA

Code:

NCT06052826

Conditions

B-Cell Non-Hodgkin Lymphoma

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Not accepted

Interventions

Best Practice

Cognitive Intervention

Comprehensive Geriatric Assessment

Nutritional Intervention

Physical Therapy

IberdomideStudy of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Recruiting

PHASE2

Sponsor:

Memorial Sloan Kettering Cancer Center

Location:

Basking Ridge NJ, Middletown NJ, Montvale NJ, Commack NYshow 3 more

Code:

NCT05354557

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Iberdomide

Arlocabtagene AutoleucelStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting

PHASE2

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Location:

Birmingham AL, Gilbert AZ, Little Rock AR, Los Angeles CAshow 34 more

Code:

NCT06297226

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Arlocabtagene Autoleucel (BMS-986393)

TeclistamabLimited-duration Teclistamab

Recruiting

PHASE2

Sponsor:

Abramson Cancer Center at Penn Medicine

Location:

Philadelphia PA

Code:

NCT05932680

Conditions

Myeloma Multiple

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Off Drug Surveillance

Prehabilitation ExercisePrehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Recruiting

Sponsor:

Dana-Farber Cancer Institute

Location:

Boston MA

Code:

NCT05706766

Conditions

Multiple Myeloma

Stem Cell Transplant Complications

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PARE

Waitlist Control Group